This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abdel-Hady, E.-S. Articles by Hampson, I. N. Search for Related Content PubMed PubMed Citation Articles by Abdel-Hady, E.-S. Articles by Hampson, I. N.

Immunological and Viral Factors Associated with the Response of Vulval Intraepithelial Neoplasia to Photodynamic Therapy¹

University of Manchester, Academic Department of Obstetrics and Gynaecology and Reproductive Health Care, St. Mary’s Hospital, Manchester M13 OJH [E-S. A-H., P. M-H., H. C. K., I. N. H.]; Departments of Immunology [M. D-K., P. L. S.], and Experimental Radiation Oncology [J. V. M.], Paterson Institute for Cancer Research, Christie Hospital, Manchester M20 4BX; and Department of Virology, Manchester Royal Infirmary, Manchester M13 9PL [G. C.], United Kingdom

Topical 5-aminolevulinic acid-based photodynamic therapy (PDT) has produced complete response rates of >90% for nonmelanoma skin carcinomas, which are mostly human papillomavirus (HPV) negative. Using a similar treatment protocol, we observed a short-term response in only one third (10 of 32) of high-grade vulval intraepithelial neoplasia (VIN 2–3) lesions. Unifocal lesions were found more responsive than multifocal and pigmented lesions. Animal model studies have suggested that long-term PDT response involves an immune reaction in which CTLs play a crucial role. In this study, we have assessed: (a) HPV infection; (b) HLA expression; and (c) immune infiltrating cells in VIN biopsies from responders and nonresponders to determine whether these factors may limit response to topical 5-aminolevulinic acid-based PDT. Tissues from normal vulva (n = 9), vulval carcinoma (n = 11), and VIN (32 patients from which 19 pre- and 43 post-PDT biopsies were taken) were investigated for immune cell infiltration and HLA class I expression by immunohistochemistry and HPV infection by PCR. There was a greater likelihood of HPV positivity associated with a lack of response of VIN to PDT (P = 0.002), and VIN nonresponders were more likely to show HLA class I loss compared with responders (P = 0.030). HLA class I down-regulation was significantly greater in the carcinomas (82%, total loss) than the VIN (28%, 19%, total loss; and 9%, allele loss; P = 0.004). None of the cases with class I down-regulation responded to PDT, whereas 3 of 6 (50%) of cases that showed total class I loss subsequently developed superficial invasion. Compared with normal vulval skin, VIN lesions showed increased infiltration by CD4 (T-helper) and CD68 (macrophages) but not CD1a (Langerhans cells) or CD8 (CTLs). There was, however, a significant increase of CD8 infiltration in posttreatment VIN responders compared with nonresponders (P = 0.0001). These data clearly support the contention that high-risk HPV infection and lack of cell-mediated immunity may play a role in the observed poor response of lower genital lesions to topical PDT.

This article has been cited by other articles:

				M. van Seters, I. Beckmann, C. Heijmans-Antonissen, M. van Beurden, P. C. Ewing, F. J. Zijlstra, T. J.M. Helmerhorst, and A. KleinJan Disturbed Patterns of Immunocompetent Cells in Usual-Type Vulvar Intraepithelial Neoplasia Cancer Res., August 15, 2008; 68(16): 6617 - 6622. [Abstract] [Full Text] [PDF]

				U. Winters, S. Daayana, J. T. Lear, A. E. Tomlinson, E. Elkord, P. L. Stern, and H. C. Kitchener Clinical and Immunologic Results of a Phase II Trial of Sequential Imiquimod and Photodynamic Therapy for Vulval Intraepithelial Neoplasia Clin. Cancer Res., August 15, 2008; 14(16): 5292 - 5299. [Abstract] [Full Text] [PDF]

				M. I.E. van Poelgeest, M. van Seters, M. van Beurden, K. M.C. Kwappenberg, C. Heijmans-Antonissen, J. W. Drijfhout, C. J.M. Melief, G. G. Kenter, T. J.M. Helmerhorst, R. Offringa, et al. Detection of Human Papillomavirus (HPV) 16-Specific CD4+ T-cell Immunity in Patients with Persistent HPV16-Induced Vulvar Intraepithelial Neoplasia in Relation to Clinical Impact of Imiquimod Treatment Clin. Cancer Res., July 15, 2005; 11(14): 5273 - 5280. [Abstract] [Full Text] [PDF]

				L. J. C. Smyth, M. I. E. van Poelgeest, E. J. Davidson, K. M. C. Kwappenberg, D. Burt, P. Sehr, M. Pawlita, S. Man, J. K. Hickling, A. N. Fiander, et al. Immunological Responses in Women with Human Papillomavirus Type 16 (HPV-16)-Associated Anogenital Intraepithelial Neoplasia Induced by Heterologous Prime-Boost HPV-16 Oncogene Vaccination Clin. Cancer Res., May 1, 2004; 10(9): 2954 - 2961. [Abstract] [Full Text] [PDF]

				E. J. Davidson, C. M. Boswell, P. Sehr, M. Pawlita, A. E. Tomlinson, R. J. McVey, J. Dobson, J. St. C. Roberts, J. Hickling, H. C. Kitchener, et al. Immunological and Clinical Responses in Women with Vulval Intraepithelial Neoplasia Vaccinated with a Vaccinia Virus Encoding Human Papillomavirus 16/18 Oncoproteins Cancer Res., September 15, 2003; 63(18): 6032 - 6041. [Abstract] [Full Text] [PDF]

				M. Stanley Chapter 17: Genital Human Papillomavirus Infections--Current and Prospective Therapies J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 117 - 124. [Abstract] [Full Text] [PDF]

				E. J. Davidson, J. A. Davidson, J. C. Sterling, P. J. W. Baldwin, H. C. Kitchener, and P. L. Stern Association between Human Leukocyte Antigen Polymorphism and Human Papillomavirus 16-positive Vulval Intraepithelial Neoplasia in British Women Cancer Res., January 15, 2003; 63(2): 400 - 403. [Abstract] [Full Text] [PDF]

				A. M. Kaufmann, P. L. Stern, E. M. Rankin, H. Sommer, V. Nuessler, A. Schneider, M. Adams, T. S. Onon, T. Bauknecht, U. Wagner, et al. Safety and Immunogenicity of TA-HPV, a Recombinant Vaccinia Virus Expressing Modified Human Papillomavirus (HPV)-16 and HPV-18 E6 and E7 Genes, in Women with Progressive Cervical Cancer Clin. Cancer Res., December 1, 2002; 8(12): 3676 - 3685. [Abstract] [Full Text] [PDF]

				S. O. Gollnick, L. Vaughan, and B. W. Henderson Generation of Effective Antitumor Vaccines Using Photodynamic Therapy Cancer Res., March 1, 2002; 62(6): 1604 - 1608. [Abstract] [Full Text] [PDF]